1
|
Regulatory and Developmental Aspects of Biomarkers in the Treatment of Ocular Surface Disease. Eye Contact Lens 2019; 46 Suppl 2:S106-S108. [PMID: 31283553 DOI: 10.1097/icl.0000000000000639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The ideal biomarker would be a simple laboratory or clinical evaluation before treatment, which would predict subsequent therapeutic response. This might include selection of which patients might respond to that treatment. While other disciplines such as neurology and oncology have biomarkers, ophthalmology is limited to one-elevated intraocular pressure as a surrogate for progressive glaucomatous field loss. US law in 2016 required the Food and Drug Administration (FDA) to set up a system to qualify biomarkers. The system now exists-with most validated or pending biomarkers limited to safety and infection. The American Academy of Ophthalmology selected dry eye disease as one of three diseases in which to standardize outcomes in ophthalmology research. There have been a number of biomarkers proposed for evaluating ocular surface disease and its treatment. None currently meets the scientific or regulatory basis for being a valid biomarker-however, additional research may result in validity. Given the FDA's scientific basis, it is unlikely that an unproven biomarker could be used for regulatory approval, even for a "SubPart H" conditional new drug application. Elsewhere in ophthalmology, we know that even patients who share the same disease gene or mutation may differ substantially in penetrance and clinical expression. Thus, it is not unexpected that ocular surface disease, a heterogeneous disease with a variable presentation of signs and symptoms, has yet to have validated biomarkers that reach the level of evidence that allows their use for diagnosis, prognosis, therapy, and for making decisions in drug development.
Collapse
|
2
|
Zhang L, Masetti G, Colucci G, Salvi M, Covelli D, Eckstein A, Kaiser U, Draman MS, Muller I, Ludgate M, Lucini L, Biscarini F. Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy. Sci Rep 2018; 8:8386. [PMID: 29849043 PMCID: PMC5976672 DOI: 10.1038/s41598-018-26700-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 05/15/2018] [Indexed: 12/12/2022] Open
Abstract
Graves’ Disease (GD) is an autoimmune condition in which thyroid-stimulating antibodies (TRAB) mimic thyroid-stimulating hormone function causing hyperthyroidism. 5% of GD patients develop inflammatory Graves’ orbitopathy (GO) characterized by proptosis and attendant sight problems. A major challenge is to identify which GD patients are most likely to develop GO and has relied on TRAB measurement. We screened sera/plasma from 14 GD, 19 GO and 13 healthy controls using high-throughput proteomics and miRNA sequencing (Illumina’s HiSeq2000 and Agilent-6550 Funnel quadrupole-time-of-flight mass spectrometry) to identify potential biomarkers for diagnosis or prognosis evaluation. Euclidean distances and differential expression (DE) based on miRNA and protein quantification were analysed by multidimensional scaling (MDS) and multinomial regression respectively. We detected 3025 miRNAs and 1886 proteins and MDS revealed good separation of the 3 groups. Biomarkers were identified by combined DE and Lasso-penalized predictive models; accuracy of predictions was 0.86 (±0:18), and 5 miRNA and 20 proteins were found including Zonulin, Alpha-2 macroglobulin, Beta-2 glycoprotein 1 and Fibronectin. Functional analysis identified relevant metabolic pathways, including hippo signaling, bacterial invasion of epithelial cells and mRNA surveillance. Proteomic and miRNA analyses, combined with robust bioinformatics, identified circulating biomarkers applicable to diagnose GD, predict GO disease status and optimize patient management.
Collapse
Affiliation(s)
- Lei Zhang
- Cardiff University, School of Medicine, Division of Infection & Immunity, Cardiff, UK
| | - Giulia Masetti
- Cardiff University, School of Medicine, Division of Infection & Immunity, Cardiff, UK.,Parco Tecnologico Padano, Bioinformatics Unit, Lodi, Italy
| | - Giuseppe Colucci
- Università degli Studi di Milano, Fondazione Ca' Granda IRCCS, Department of Clinical Sciences and Community Health, Milan, Italy
| | - Mario Salvi
- Università degli Studi di Milano, Fondazione Ca' Granda IRCCS, Department of Clinical Sciences and Community Health, Milan, Italy
| | - Danila Covelli
- Università degli Studi di Milano, Fondazione Ca' Granda IRCCS, Department of Clinical Sciences and Community Health, Milan, Italy
| | - Anja Eckstein
- University Hospital Essen/University of Duisburg-Essen, Department of Ophthalmology, Essen, Germany
| | - Ulrike Kaiser
- University Hospital Essen/University of Duisburg-Essen, Department of Ophthalmology, Essen, Germany
| | - Mohd Shazli Draman
- Cardiff University, School of Medicine, Division of Infection & Immunity, Cardiff, UK
| | - Ilaria Muller
- Cardiff University, School of Medicine, Division of Infection & Immunity, Cardiff, UK
| | - Marian Ludgate
- Cardiff University, School of Medicine, Division of Infection & Immunity, Cardiff, UK
| | - Luigi Lucini
- Università Cattolica del Sacro Cuore, Department for Sustainable food process, Piacenza, Italy
| | - Filippo Biscarini
- Cardiff University, School of Medicine, Division of Infection & Immunity, Cardiff, UK. .,CNR (National Council for Research), Institute of Biology and Biotechnology in Agriculture (IBBA), Milan, Italy.
| |
Collapse
|
3
|
Berger F, Reiser MF. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences? Theranostics 2013; 3:943-52. [PMID: 24396505 PMCID: PMC3881096 DOI: 10.7150/thno.7445] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2013] [Accepted: 10/21/2013] [Indexed: 12/16/2022] Open
Abstract
Minimally invasive biomarkers for early cancer detection and monitoring of personalized therapies are of high importance to further improve prognosis in oncological disease. MicroRNAs (miRNAs) are small regulatory RNAs in humans and play a key role in carcinogenesis. In recent years they have emerged as promising biomarkers in oncology. miRNA profiling has demonstrated its capacity for sub-classifying tumors and monitoring of therapeutic effects. Different expression profiles of miRNAs in cancer and the stability of circulating miRNAs potentially provide a clinically accessible molecular monitoring tool of malignant tissues and its response to therapies. Clinical imaging including the modalities PET/CT and MRI is well established for characterizing tumor tissue and sub-classifying morphological, metabolic or vascular treatment response in cancer. Sophisticated clinical imaging biomarkers for cancer detection and monitoring should now been correlatively applied to further validate the potential of miRNAs as oncologic biomarkers for the clinic.
Collapse
|
4
|
|
5
|
Abstract
Forty years after the signing of the National Cancer Act, we have produced a stunning repository of scientific information that is being translated into better therapies for patients. Although challenges remain, many solutions have been adopted, leading to early signs of progress against some of humankind's most dreadful diseases. This Prospective attempts to highlight some of the approaches that have been successful and analyze some that have not, and peers into a future in which renewal of the investment in cancer research will produce further benefits for patients.
Collapse
Affiliation(s)
- William N Hait
- Janssen, The Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA.
| |
Collapse
|
6
|
Zhang L, Ludgate ME. The search for biomarkers of disease: surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, tears, and thyroid-associated ophthalmopathy. Thyroid 2012; 22:981-3. [PMID: 23025538 DOI: 10.1089/thy.2012.2210.ed2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
7
|
Halford MM, Tebbutt NC, Desai J, Achen MG, Stacker SA. Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer. COLORECTAL CANCER 2012. [DOI: 10.2217/crc.12.9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
SUMMARY Clinical oncology experience with recently marketed antiangiogenic agents, which inhibit proteins important for tumor angiogenesis, has exposed significant limitations to their efficacy. Bevacizumab, a humanized neutralizing anti-VEGF-A monoclonal antibody, used in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal cancer, represents the best-studied clinical example of targeted antiangiogenic therapy. In this context, bevacizumab provides modestly improved progression-free and overall survival in unselected patient populations via poorly understood mechanisms. Here we review concepts central to the identification and development of biomarkers in order to refine clinical use of bevacizumab in treating colorectal cancer and outline a phenotype-driven strategy for the discovery of high-value candidate biomarkers based on large-scale screening by molecular perturbation.
Collapse
Affiliation(s)
- Michael M Halford
- Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
| | - Niall C Tebbutt
- Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
| | - Jayesh Desai
- Department of Medical Oncology, The Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia
| | - Marc G Achen
- Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia
| | - Steven A Stacker
- Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
| |
Collapse
|
8
|
Dean E, Greystoke A, Ranson M, Dive C. Biomarkers of cell death applicable to early clinical trials. Exp Cell Res 2012; 318:1252-9. [PMID: 22483936 DOI: 10.1016/j.yexcr.2012.03.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2012] [Revised: 03/19/2012] [Accepted: 03/19/2012] [Indexed: 01/12/2023]
Abstract
The development of biomarkers of cell death to reflect tumor biology and drug-induced response has garnered interest with the development of several classes of drugs aimed at decreasing the cellular threshold for apoptosis and exploiting pre-existing oncogenic stresses. These novel anticancer drugs, directly targeted to the apoptosis regulatory machinery and aimed at abrogating survival signaling pathways, are entering early clinical trials provoking the question of how to monitor their impact on cancer patients. The parallel development of drugs with predictive biomarkers and their incorporation into early clinical trials are anticipated to support the pharmacological audit trail, to speed the development and reduce the attrition rate of novel drugs whose objective is to provoke tumor cell death. Tumor biopsies are an ideal matrix to measure apoptosis, but surrogate less invasive biomarkers such as blood samples and functional imaging are less challenging to acquire clinically. Archetypal and exploratory examples illustrating the importance of biomarkers to drug development are given. This review explores the substantive challenges associated with the validation, deployment, interpretation and utility of biomarkers of cell death and reviews recent advances in their incorporation in preclinical and early clinical trial contexts.
Collapse
Affiliation(s)
- Emma Dean
- Paterson Institute for Cancer Research, The University of Manchester, Withington, Manchester, UK.
| | | | | | | |
Collapse
|
9
|
|
10
|
Abstract
The drug discovery and development enterprise, traditionally an industrial juggernaut, has spanned into the academic arena that is partially motivated by the National Institutes of Health Roadmap highlighting translational science and medicine. Because drug discovery and development represents a pipeline of basic to clinical investigations, it meshes well with the "bench to the bedside" prime directive of translational medicine. The renewed interest in drug discovery and development in academia provides an opportunity to rethink the hiearchary of studies with the hope of improving the staid approaches that have been criticized for lacking innovation. One area that has received limited attention concerns the use of pharmacokinetic and pharmacodynamic studies in the drug-development process. Using anticancer drug development as a focus, this review will address past and current deficencies in how pharmacokinetic/pharmacodynamic studies are conducted and offer new strategies that might bridge the gap between preclinical and clinical trials.
Collapse
Affiliation(s)
- James M Gallo
- Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY, USA.
| |
Collapse
|
11
|
Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treat Rev 2011; 37:579-89. [PMID: 21592671 DOI: 10.1016/j.ctrv.2011.04.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2011] [Revised: 04/14/2011] [Accepted: 04/18/2011] [Indexed: 12/20/2022]
Abstract
Circulating tumor cells (CTCs) have received a lot of attention from both researchers and clinicians because of their prognostic value for progression-free and overall survival in selected tumor types. CTCs are readily available by single venipuncture, thereby posing little burden on the patient and allowing for repeated, sequential sampling during therapy. Nowadays, the sensitivity of several CTC detection and capture techniques allow for further characterization and analysis of specific targets of interest on the CTC itself. These techniques have given CTCs the potential to be used as a pharmacodynamic read-out in drug development. In this review, we explore the utility of CTCs as a pharmacodynamic biomarker in early clinical oncological trials. We present an overview of current literature on assays for CTCs as pharmacodynamic biomarker, their different targets of interest and their level of validation, followed by discussion of their limitations.
Collapse
|
12
|
|
13
|
Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, Reale MG, Frati L, Midulla C. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010; 31:411-5. [PMID: 20490961 DOI: 10.1007/s13277-010-0049-1] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2010] [Accepted: 04/29/2010] [Indexed: 10/19/2022] Open
Abstract
The objective of the present study was to investigate in healthy young women the fluctuations in serum concentration of human epididymal secretory protein human epididymis-specific protein 4 (HE4) and CA125 during the phases of the menstrual cycle and the correlation between HE4 and CA125 values and age. Forty women with regular menstrual cycles were included in the study. Pelvic and transvaginal ultrasound were performed in order to exclude ovarian pathologies. Blood samples were collected at follicular (FP), ovulatory (OP), and luteal (LP) phases of the hormonal cycle. The values of HE4 (expressed as picomoles per liter) observed were (mean ± SEM) 39.1 ± 1.1 (FP), 45.3 ± 1.19 (OP), and 42.0 ± 1.3 (LP). The difference between FP and OP was statistically significant (p = 0.0002). By contrast, serum CA125 levels (expressed as units per milliliter) were 14.35 ± 0.66 (FP), 13.15 ± 0.54 (OP), and 13.70 ± 0.54 (LP), respectively. The levels of HE4 observed in serum samples of women below 35 years were 37.5 ± 1.28 in the FP, 46.6 ± 1.4 in the OP, and 42.8 ± 1.49 in the LP. In this group, a statistically significant difference was observed in the FP compared with the OP (p < 0.0001), whereas no statistically significant difference was observed during the different hormonal phases in the group of women over 35. In conclusion, the correct interpretation of laboratory data is essential to define a threshold of normality, and for what concerns HE4 levels, the menstrual cycle phase-dependent variability appears indicated in the interpretation of the results.
Collapse
|
14
|
Clark DP. Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. Expert Rev Mol Diagn 2010; 9:787-94. [PMID: 19895224 DOI: 10.1586/erm.09.62] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Most of the currently utilized predictive biomarkers for therapeutic decision-making provide information regarding the presence or absence of the drug target but reveal little about the functional circuitry of the signaling network that the drug must also impact. Ex vivo biomarkers are dynamic molecular markers evoked from living tumor cells after removal from the patient. Such ex vivo biomarkers provide valuable mechanistic information that may facilitate drug development and guide the clinical selection of targeted therapeutics.
Collapse
Affiliation(s)
- Douglas P Clark
- Department of Oncology, The Johns Hopkins School of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
| |
Collapse
|
15
|
Yu YB. Delivered dose: a drug-centric phenotype for chemotherapy dose individualization. Pharm Res 2009; 26:1803-6. [PMID: 19495942 DOI: 10.1007/s11095-009-9913-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2009] [Accepted: 05/20/2009] [Indexed: 10/20/2022]
Abstract
It is pointed out that genotype-based approaches are unlikely to be effective at dose individualization. Delivered dose, which refers to the amount of drug delivered to the point of action to be measured by quantitative imaging techniques, is a drug-centric phenotype that separates pharmacokinetic effects from pharmacodynamic effects. Delivered dose serves as a midway measurable numeric parameter between drug administration and therapy outcome. One potential way to reduce chemotherapy outcome variation is to individualize prescribed drug so that uniform delivered dose is achieved across the patient population.
Collapse
Affiliation(s)
- Y Bruce Yu
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, USA.
| |
Collapse
|
16
|
Hunter JM, Paramithiotis E. Protein biomarker quantification by mass spectrometry. ACTA ACUST UNITED AC 2009; 4:11-20. [DOI: 10.1517/17530050902929214] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
17
|
|
18
|
|